Core Insights - WuXi AppTec (603259.SH, 2359.HK) reported its Q3 financial results on October 26, 2025, showcasing strong growth in revenue and profit [1] Financial Performance - The company achieved a cumulative revenue of 32.86 billion yuan for the first three quarters, representing a year-on-year increase of 18.6% [1] - Adjusted Non-IFRS net profit attributable to the parent company reached 10.54 billion yuan, marking a year-on-year growth of 43.4%, which has already matched the total scale of the previous year [1] - The third quarter alone saw record-high revenue and adjusted net profit, indicating the best quarterly performance in the company's history [1]

新京报贝壳财经讯 10月26日，药明康德公告称，公司全资子公司上海药明拟以28亿元的基准股权转让 价款，向上海世和融企业管理咨询有限公司及上海世和慕企业管理咨询有限公司转让其所持有的上海康 德弘翼医学临床研究有限公司和上海药明津石医药科技有限公司100%股权。本次交易完成后，公司将 不再持有目标公司的股权。本次出售康德弘翼及津石医药100%股权，是本公司基于聚焦CRDMO业务模 式，专注药物发现、实验室测试及工艺开发和生产服务考虑所实施，可为公司加速全球化能力和产能的 投放提供资金支持，符合公司发展战略和长远利益。目标公司主要经营临床研究服务业务。受让方均系 高瓴投资(以下简称"高瓴")通过旗下私募股权基金为本次交易目的新设立的公司。高瓴专注于医疗健 康、制造业、绿色能源、硬科技和消费科技等领域，投资横跨早期风险投资、私募股权投资以及并购投 资等阶段，投资人主要来自于全球机构投资人。 ...

2025年10月26日，药明康德(603259.SH/2359.HK)发布最新财务数据：前三季度实现营业收入328.6亿 元，同比增长18.6%，三大利润口径上的增速均高于营收水平。药明康德并将全年营收指引上调至435- 440亿元，这是今年内的第二次上调，预计全年持续经营业务收入增速介于17%到18%之间。 ...

Core Insights - WuXi AppTec (603259.SH/2359.HK) reported a strong performance in Q3 2025, achieving a record quarterly revenue exceeding 12 billion yuan [1] - The company's revenue for the first three quarters reached 32.86 billion yuan, reflecting a year-on-year growth of 18.6% [1] - Profit growth across three metrics also showed double-digit increases, indicating robust operational efficiency and financial management [1] - Operating cash flow for the first three quarters was 10.87 billion yuan, marking a significant year-on-year increase of 35% [1]

本次交易项下转让方向受让方出售其所持目标公司1和目标公司2的100%股权为一项完整交易中不可分 割的组成部分。本次交易完成后，公司及合并报表范围内的下属子企业将不再持有目标公司的股权。 智通财经APP讯，药明康德(603259.SH)发布公告，公司全资子公司上海药明康德新药开发有限公司(以 下简称"上海药明"或"转让方")拟以人民币28亿元(为基准股权转让价款，最终股权转让价款(定义见下， 下同)将基于交易协议的相关约定进行调整)的对价向上海世和融企业管理咨询有限公司(以下简称"受让 方1")及上海世和慕企业管理咨询有限公司(以下简称 "受让方2"，与受让方1以下合称为"受让方"或"交 易对方")转让其所持有的上海康德弘翼医学临床研究有限公司(以下简称"康德弘翼"或"目标公司1")和上 海药明津石医药科技有限公司(以下简称"津石医药"或"目标公司2"，与目标公司1以下合称"目标公司") 100%股权。 本次出售康德弘翼及津石医药100%股权，是公司基于聚焦CRDMO业务模式，专注药物发现、实验室测 试及工艺开发和生产服务考虑所实施，可为公司加速全球化能力和产能的投放提供资金支持，符合公司 发展战略和长远利益。 ...

Core Viewpoint - WuXi AppTec (603259.SH) announced the sale of 100% equity in two subsidiaries, Shanghai Kande Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd., for a base price of RMB 2.8 billion, aiming to focus on its CRDMO business model and enhance global capabilities and capacity [1][2]. Group 1 - The transaction involves the complete transfer of equity in both target companies as an indivisible part of a comprehensive deal [1]. - The sale aligns with the company's strategy to concentrate on drug discovery, laboratory testing, and process development and production services [2]. - The target companies generated approximately RMB 1.16 billion in revenue from January to September 2025, accounting for about 3.5% of the company's total revenue for the same period [2]. Group 2 - The net profit of the target companies for the same period was approximately RMB 90 million, representing about 0.7% of the company's net profit [2]. - The transaction is expected to provide financial support for the company's accelerated global capacity deployment [2].

Core Insights - WuXi AppTec (603259.SH) reported a revenue of RMB 32.857 billion for the first three quarters of 2025, representing a year-on-year growth of 18.61% [1] - The net profit attributable to shareholders reached RMB 12.076 billion, showing a significant increase of 84.84% year-on-year [1] - The net profit after deducting non-recurring gains and losses was RMB 9.522 billion, up by 42.51% year-on-year [1] Group 1: Chemical Business - The chemical business generated revenue of RMB 25.98 billion, reflecting a year-on-year growth of 29.3% [1] - The small molecule drug discovery ("R") business has successfully synthesized and delivered over 430,000 new compounds to clients in the past twelve months [1] - In the first three quarters of 2025, the company converted 250 molecules from research to development [1] Group 2: Small Molecule Development and Manufacturing (D&M) - The small molecule D&M business achieved revenue of RMB 14.24 billion, with a year-on-year increase of 14.1% [2] - A total of 621 new molecules were added to the small molecule D&M pipeline in the first three quarters of 2025, bringing the total to 3,430, which includes 80 commercial projects and 87 Phase III clinical projects [2] - The company successfully passed FDA inspections at its Changzhou and Taixing API bases with zero defects in March 2025 [2] Group 3: TIDES Business - The TIDES business (oligonucleotides and peptides) experienced rapid growth, with revenue reaching RMB 7.84 billion, a year-on-year increase of 121.1% [3] - As of September 2025, TIDES' order backlog grew by 17.1% year-on-year [3] - The number of clients served in TIDES D&M increased by 12%, and the number of molecules served rose by 34% [3]

证券代码：603259 证券简称：药明康德 公告编号：临 2025-068 无锡药明康德新药开发股份有限公司 第三届董事会第二十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）于 2025 年 10 月 10 日及 2025 年 10 月 23 日向本公司全体董事发出会议通知及会议 材料，全体董事一致同意豁免本次会议的通知期限要求，并以现场结合通讯表决 方式于 2025 年 10 月 24 日按期在公司会议室召开第三届董事会第二十六次会议。 本次董事会会议应出席董事 11 人，实际出席董事 11 人，会议由董事长 Ge L（i 李 革）主持。本次董事会符合《中华人民共和国公司法》和《无锡药明康德新药开 发股份有限公司章程》关于召开董事会会议的规定。 二、董事会会议审议情况 （一）审议通过《关于公司 2025 年第三季度报告的议案》 同意《无锡药明康德新药开发股份有限公司 2025 年第三季度报告》的相关 内容。 上述议案已 ...

Core Insights - WuXi AppTec (603259.SH) reported a revenue of 32.857 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 18.61% [1] - The net profit attributable to shareholders reached 12.076 billion yuan, with a significant year-on-year increase of 84.84% [1] - The net profit excluding non-recurring gains and losses was 9.522 billion yuan, reflecting a year-on-year growth of 42.51% [1] Chemical Business - The chemical business generated revenue of 25.98 billion yuan, marking a year-on-year increase of 29.3% [1] - The small molecule drug discovery ("R") business has successfully synthesized and delivered over 430,000 new compounds for clients in the past twelve months [1] - The company has converted 250 molecules from research to development (R to D) in the first three quarters of 2025 [1] Small Molecule Development and Manufacturing - The small molecule development and manufacturing (D&M) business reported revenue of 14.24 billion yuan, showing a year-on-year growth of 14.1% [2] - A total of 621 new molecules were added to the small molecule D&M pipeline in the first three quarters of 2025, bringing the total to 3,430, which includes 80 commercial projects and 87 clinical phase III projects [2] - The company successfully passed FDA inspections at its Changzhou and Taixing API bases with zero defects in March 2025 [2] TIDES Business - The TIDES business (oligonucleotides and peptides) experienced rapid growth, with revenue reaching 7.84 billion yuan, a year-on-year increase of 121.1% [3] - As of September 2025, TIDES orders on hand grew by 17.1% year-on-year, with the number of clients served increasing by 12% and the number of molecules served rising by 34% [3] - The company completed the capacity expansion for peptides in Taixing ahead of schedule, increasing the total volume of solid-phase synthesis reactors to over 100,000 liters [3]

格隆汇10月26日丨药明康德披露业绩，2025年前三季度实现营收328.6亿元，同比增长18.6%；归属于上 市公司股东的净利润达120.8亿元，同比增长84.8%；第三季度净利润35.15亿元，同比增长53.27%。 ...